Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Cambridge, MA.
相关临床试验
6
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
2
33.3%
已完成
1
16.7%
招募中
1
16.7%
终止
2
33.3%
暂无批准数据
- DNA Damage Response inhibitors surpassed $7 billion in global sales in 2025, with the broader oncology market projected to approach $500 billion by 2032. - Onco-Innovations is advancing ONC010, a nanoparticle-encapsulated PNKP inhibitor that extended median survival to 60 days versus 23 days in PTEN-deficient colorectal cancer mouse models. - The company holds exclusive global rights across three IP layers—core molecules, nanoparticle delivery, and synthetic lethality applications—with a first-in-human phase 1 trial anticipated for late 2026. - Artios Pharma, MD Anderson, and Repare Therapeutics have all generated clinical signals from novel DDR targets beyond PARP, confirming the sector's investable maturity.
- Flagship Pioneering and Amazon Web Services announced a strategic collaboration to accelerate breakthrough life sciences companies through cloud computing and AI capabilities. - Early-stage Flagship companies will receive AWS cloud credits, technical support, and AI services to build digitally native platforms across human health and sustainability domains. - The partnership aims to transform drug discovery processes by providing scalable infrastructure that enables rapid experimentation and seamless transition from discovery to deployment. - AWS will serve as the preferred cloud provider for Flagship's portfolio, which includes over 40 companies such as Moderna and operates with $14 billion in assets under direction.
- Yatiri Bio's AI-driven ProteoCharts™ platform demonstrated 100% concordance between biomarker-guided predictions and clinical outcomes in a blinded study of Foghorn Therapeutics' FHD-286 for relapsed/refractory AML and MDS patients. - The validation study analyzed eight blinded pre-treatment blood samples from a Phase 1 trial, correctly identifying patients who achieved complete or partial responses versus those with stable disease or treatment failure. - Following the successful validation, Yatiri Bio and Foghorn Therapeutics signed a collaboration agreement worth over $40 million in clinical and sales milestones to advance FHD-286 development using biomarker-guided patient selection. - The breakthrough validates precision medicine approaches for oncology patient stratification and could significantly improve clinical trial success rates by matching patients to appropriate therapies before treatment begins.
- Foghorn Therapeutics raised $50 million in equity financing at a 30% premium to market price from leading biotech investors including BVF Partners, Deerfield Management, and Flagship Pioneering. - The company's Phase 1 trial of FHD-909, a first-in-class SMARCA2 inhibitor targeting SMARCA4-mutant cancers including NSCLC, is progressing as planned with enrollment ongoing. - Multiple degrader programs are advancing toward IND filings in 2026, including selective CBP degraders for ER+ breast cancer and EP300 degraders for hematologic malignancies. - The financing extends the company's cash runway to the first half of 2028, with total cash reserves of approximately $208.9 million to support continued pipeline development.
- 4D Molecular Therapeutics has appointed Kristian Humer as Chief Financial Officer to lead financial strategy as the company advances multiple Phase III programs and prepares for commercial readiness. - Humer brings over two decades of experience in corporate finance and healthcare investment banking, having previously served as Managing Director at Citi's Healthcare Investment Banking Group and CFO at publicly traded companies Foghorn Therapeutics and Viridian Therapeutics. - The appointment comes as 4DMT's lead product candidate 4D-150 progresses through Phase III development for wet age-related macular degeneration, with a second indication in diabetic macular edema. - 4D-150 is designed as a backbone therapy providing multi-year sustained delivery of anti-VEGF agents with a single intravitreal injection, potentially reducing treatment burden for blinding retinal vascular diseases.
- Foghorn Therapeutics reported continued progress in its Phase 1 dose escalation trial of FHD-909 for SMARCA4-mutated cancers, primarily targeting non-small cell lung cancer patients. - The company's selective CBP degrader entered non-GLP toxicology studies in Q4 2025 with potential applications in EP300-mutant cancers and ER+ breast cancer, targeting IND readiness in 2026. - Preclinical data showed the selective EP300 degrader demonstrated broad anti-tumor activity across over 70% of hematological malignancy sub-lineages tested, differentiating it from dual CBP/EP300 approaches. - The selective ARID1B degrader program is advancing toward in vivo proof of concept in 2026, with potential relevance in up to 5% of solid tumors including endometrial, gastric, and bladder cancers.
- Foghorn Therapeutics announced significant progress for its selective ARID1B degrader program targeting endometrial, gastric, and bladder cancers with high unmet medical needs. - The company will present breakthrough findings at the 8th Annual TPD and Induced Proximity Summit as part of a keynote plenary session on October 29, 2025. - Foghorn's selective CBP and EP300 degrader programs are progressing toward Investigational New Drug enabling studies, expanding the company's protein degrader pipeline. - The developments represent potential first-in-class targeting of challenging chromatin regulatory proteins through the company's proprietary Gene Traffic Control platform.
- IQVIA and Flagship Pioneering announced a strategic collaboration in August 2025 to accelerate breakthrough life sciences companies using AI-powered analytics and clinical trial expertise. - The partnership focuses on three core areas: drug development strategy and analytics, clinical development, and asset valuation and due diligence for Flagship's 40+ biotech portfolio companies. - IQVIA's deployment of over 50 NVIDIA-built AI agents trained on 1.2 billion health records aims to reduce patient recruitment bottlenecks and accelerate clinical trial timelines. - The collaboration leverages Flagship's $14 billion in assets under management and IQVIA's $32.1 billion R&D backlog to enhance commercial viability of emerging biotech ventures.
- Foghorn Therapeutics' FHD-909, a SMARCA2 inhibitor, is progressing in Phase 1 trials for SMARCA4-mutated cancers, with NSCLC as the primary target, and combination data with pembrolizumab and KRAS inhibitors will be presented at AACR. - The company achieved selective degradation of ARID1B, a synthetic lethal target in solid tumors, and plans to update on its progress in 2025, while also advancing CBP and EP300 degrader programs. - Foghorn Therapeutics is collaborating with Lilly to develop novel oncology medicines, including co-development of the SMARCA2 program and additional undisclosed targets. - With a strong financial position of $243.8 million in cash reserves, Foghorn Therapeutics anticipates funding operations into 2027, supporting ongoing research and development efforts.
- Foghorn Therapeutics halts independent development of FHD-286 with decitabine for relapsed/refractory AML due to insufficient response rates in Phase 1 trial. - The company will now focus on its proprietary pipeline and Lilly collaboration programs, including the clinical-stage SMARCA2 inhibitor FHD-909. - Foghorn Therapeutics reported $267.4 million in cash reserves as of September 30, 2024, securing operational runway into 2027. - Full results from the FHD-286 Phase 1 trial are expected to be presented at a medical conference in 2025.
